Modern veterinary vaccines and the Shaman's apprentice

Comparative Immunology, Microbiology and Infectious Diseases

Volumn 26, Issue 5-6, 2003, Pages 389-400

  Carter, Philip B ^a   Carmichael, L E ^b  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

^b Cornell University ^*  (United States)

Author keywords

Companion animal; Food animal; Vaccine; Vaccine advisory committee; Veterinary

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; BACTERIAL VACCINE; CHOLERA TOXIN; CHOLERA TOXIN B SUBUNIT; CYTOKINE; DNA VACCINE; IMMUNOLOGICAL ADJUVANT; IMMUNOSTIMULATING AGENT; VACCINE; VIRUS VECTOR;

ALTERNATIVE MEDICINE; CHLAMYDIASIS; DNA VECTOR; DRUG EFFICACY; DRUG SAFETY; GENE DELIVERY SYSTEM; GENETICALLY MODIFIED FOOD; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; LEPTOSPIROSIS; LYME DISEASE; MEDICAL TECHNOLOGY; NONHUMAN; REVIEW; TUBERCULOSIS; VETERINARY MEDICINE;

ANIMALIA;

EID: 0041538420     PISSN: 01479571     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0147-9571(03)00022-5     Document Type: Short Survey

References (62)

1. Pastoret P-P, Blancou J, Vannier P, Verschueren C. Veterinary vaccinology. Amsterdam: Elsevier; 1997. 853 p.
2. Peters AR. Vaccines for veterinary applications. Oxford: Butterworth-Heinemann; 1993. 347 p.
3. Espeseth DA, Myers TJ. Authorities and procedures for licensing veterinary products in the United States. In: Schultz RD, editor. Adv. veterinary medicine. Vet. Vaccines and diagnostics, vol. 41.; 1999. p. 585-93.
4. Pastoret PP, Falize P. Licensing procedures for immunological veterinary medicinal products in the European Union. Adv. Veterinary medicine. Vet. Vaccines and diagnostics, vol. 41. London: Academic Press; 1999. p. 595-607.
5. Klingborg DJ, Hustead DR, Curry-Galvin EA, Gumley NR, Henry SC, Bain FT, Paul MA, Boothe DM, Blood KS, Huxsoll DL, Reynolds DL, Riddell Jr. MG, Reid JS, Short CR. AVMA council on biologic and therapeutic agents report on cat and dog vaccines. JAVMA 2002; 221(10):1401-7.
6. Soulebot JP, Folkers C, Taylor J, Pastoret PP. Properties of vaccines. In: Pasterot PP, Blancou J, Vannier P, Verschueren C, editors. Veterinary vaccinology. Amsterdam: Elsevier; 1997. p. 159-66.
7. Carmichael LE. Canine viral vaccines at a turning point-a personal perspective. In: Schultz RD, editor. Veterinary medicine. Vet. Vaccines and diagnostics, vol. 41. London: Academic Press; 1999. p. 289-308.
8. Gaudry D. International association of biological standardization and international harmonization. In: Schultz RD, editor. Veterinary medicine. Vet. Vaccines and diagnostics, vol. 41. London: Academic Press; 1999. p. 609-14.
9. Bazin H. The eradication of smallpox. London: Academic Press; 2000.
10. Dubos R. Pasteur and modern science. Masterworks, Garden City, New York, 1960.
11. Priest SA. Holistic remedies are getting a shot in the arm. Homeopathic nosodes are being examined by some vets as an option to yearly vaccines. Dog World; January 24-30 1996.
12. Schultz RD. Emerging issue: vaccines strategies for canine viral enteritis. Proc Inf Gastroenter Sympos No Am Vet Conf 19-24 1995;.
13. Smith CA. Current concepts: are we vaccinating too much? J Am Vet Med Assoc 1995;207: 421-5.
14. Tennant BJ, Gaskell RM, Jones RC, et al. Studies on the epizootiology of canine coronavirus. Vet Rec 1993;132:7-11.
15. Appel MJG, Gillespie JH. Canine distemper virus. In: Gard S, Hallauer C, Meyer KF, editors. Virology monographs 11. New York: Springer; 1972. p. 27-48.
16. Carmichael LE. Immunization strategies in puppies - why failures? Compend Cont Ed Pract Vet 1983;5:1043-51.
17. Carmichael LE. Vaccines for dogs. In: Pastoret PP, Blancou J, Vannier P, Verschueren C, editors. Veterinary vaccinology. Amsterdam: Elsevier Science; 1997. p. 326-35.
18. Martin ML. Canine coronavirus enteritis and a recent outbreak following modified live virus vaccination. Compend Cont Educ Pract Vet 1985;7:1012-7.
19. Rikula U, Sihvonen L, Voipio HM, et al. Serum antibody response to canine distemper virus vaccines in beagle dogs. Proc, Frontiers Lab Anim Sci 1995;199.
20. Tizzard I. Risks associated with use of live vaccines. J Am Vet Med Assoc 1990;196:1851-8.
21. Wilbur LA, et al. Abortion and death in pregnant bitches associated with a canine vaccine contaminated with bluetongue virus. J Am Vet Med Assoc 1994;204:1762-5.
22. Wilson RB, Holladay JA, Cave JA. A neurologic syndrome associated with use of a canine coronavirus-parvovirus vaccine in dogs. Compend Cont Educ Pract Vet 1986;8:117-24.
23. Duval D, Giger U. Vaccine-associated immune-mediated hemolytic anaemia in the dog. J Vet Intern Med 1996;10:290-5.
24. Pitcairn RH. Dr. Pitcairn's complete guide to natural health for dogs and cats, 2nd ed. Emmaus, PA: Rodale Press; 1995.
25. Priest SA. Holistic remedies are getting a shot in the arm. Homeopathic nosodes are being examined by some vets as an option to yearly vaccines. Dog World; January 24-30 1996.
26. Starita-Mehan D. The dangers of vaccinations, and the advantages of nosodes for disease prevention. Nosode vaccination, Boring, OR: County Way Veterinary Care; 1997.
27. Yarnall C. Cat care naturally. Vermont: C.E. Tuttle, Inc; 1995.
28. Appel M. Virus infections of vertebrates. In: Horzinek MC, editor. Virus infections of carnivores, vol. 1.; 1987. p. 29-60.
29. Pastoret P-P. Les infections digestives d'origin viral chez le chien. Ann Med Vet 1984;128: 473-83.
30. Carmichael LE. Canine parvovirus immunization: myths and realities. Am Kennel Club Gazette Dec 94-102 1989;.
31. Schultz RD. Canine distemper: comparison of the leading multi-component commercial vaccines. Infect Dis Bull 1996;1-2. Millsboro, DE, Intervet.
32. Volp K, Mathews S, Timms P, Hafner L. Peptide immunization of guinea pigs against Chlamydia psittaci (GPIC agent) infection induced good vaginal secretion antibody response, in vitro neutralization, and partial protection against live challenge. Immunol Cell Biol 2001; 79(3):245-50.
33. Sandbulte J, TerWee J, Wigington K, Sabara M. Evaluation of Chlamydia psittaci subfraction preparations for their protective capacities. Vet Microbiol 1995;24:269-82.
34. Scientific Committee on Animal Health and Animal Welfare. Alexander DJ, chair. European Commission Health and Consumer Protection Directorate-General. Avian chlamydiosis as a zoonotic disease and risk reduction strategies; 16 April 2002.
35. Barr SC. Leptospirosis: new issues and considerations. Compend Contin Ed 2002;24(1):53-6.
36. Plank R, Dean D. Overview of the epidemiology, microbiology, and pathogenesis of Leptospira spp. in humans. Microbes Infect 2000;2(10):1265-76.
37. Straubinger RK, Dharma Rao T, Davidson E, Jacobson BA, Frey AB. Protection against tick-transmitted Lyme disease in dogs vaccinated with a multiantigenic vaccine. Vaccine 2001; 20(1-2):181-93.
38. Brouta F, Descamps F, Monod M, Vermout S, Losson B, Mignon B. Secreted metalloprotease gene family of Microsporum canis. Infect Immun 2002;70:5676-983.
39. DeBoer DJ, Moriello KA. Investigations of a killed dermatophyte cell-wall vaccine against infection with Microsporum canis in cats. Res Vet Sci 1995;59:110-3.
40. Lund A, Bratberg A. Cell recruitment in skin in the course of an experimental infection with Trichophyton verrucosum in a vaccinated and a non-vaccinated calf. Adv Vet Dermatol, vol. 3. Oxford: Butterworth-Heinmann; 1998. p. 272-81.
41. Orme IM. Immunology and vaccinology of tuberculosis: can lessons from the mouse be applied to the cow? Tuberculosis (Edinb) 2001;81(1-2):109-13.
42. Orme IM. The search for new vaccines against tuberculosis. J Leukoc Biol 2001;70(1):1-10.
43. Baldwin SL, D'Souza CD, Orme IM, Liu MA, Huygen K, Denis O, Tang A, Zhu L, Montgomery D, Ulmer JB. Immunogenicity and protective efficacy of DNA vaccines encoding secreted and non-secreted forms of Mycobacterium tuberculosis Ag85A. Tuber Lung Dis 1999; 79(4):251-9.
44. Carter PB, Collins FM. The route of enteric infection in normal mice. J Exp Med 1974;139(5): 1189-203.
45. Curtiss III R. Bacterial infectious disease control by vaccine development. J Clin Invest 2002; 110(8):1061-6.
46. McVey DS, Chengappa MM, Mosier DE, Stone GG, Oberst RD, Sylte MJ, Gabbert NM, Kelly-Aehle SM, Curtiss R. Immunogenicity of chi4127 phoP-Salmonella enterica serovar Typhimurium in dogs. Vaccine 2002;20(11-12):1618-23.
47. Mason HS, Arntzen CJ. Transgenic plants as vaccine production systems. Trends Biotechnol 1995;13(9):388-92.
48. Palmer KE, Arntzen CJ, Lomonosoff GP. Antigen delivery systems: transgenic plants and recombinant plant viruses. In: Ogra PL, Mestecky J, Lamm ME, Strober W, Bienenstock J, McGhee JR, editors. Mucosal immunology. San Diego: Academic Press; 1999. p. 793-807.
49. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256(5517):495-7.
50. Walmann H. Reprogramming the immune syste. Immunol Rev 2002;185:227-35.
51. Strube W. Multivalent vaccines. In: Pastoret PP, Blancou J, Vannier P, Verschueren C, editors. Veterinary vaccinology. Amsterdam: Elsevier Science BV; 1997. p. 269-72.
52. Elson CO, Ealding W. Cholera toxin feeding did not induce oral tolerance in mice and abrogated oral tolerance to an unrelated protein antigen. J Immunol 1984;133:2892-7.
53. Elson CO. Cholera toxin as a mucosal adjuvant. In: Kiyono H, Ogra PL, McGhee JR, editors. Mucosal vaccines. San Diego: Academic Press; 1996. p. 73-87.
54. Elson CO, Dertzbaugh MT. Mucosal adjuvants. In: Ogra PL, Mestecky J, Lamm ME, Strober W, Bienenstock J, McGhee JR, editors. Mucosal immunology. San Diego: Academic Press; 1999. p. 817-38.
55. Eriksson K, Holmgren J. Recent advances in mucosal vaccines and adjuvants. Curr Opin Immunol 2002;14(5):666-72.
56. Clements JD, Hartzog NM, Lyon FL. Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens. Vaccine 1988;6:269-77.
57. Dickinson BL, Clements JD. Use of Escherichia coli heat-labile enterotoxin as an oral adjuvant. In: Kiyono H, Ogra PL, McGhee JR, editors. Mucosal vaccines. San Diego: Academic Press; 1996. p. 73-87.
58. Bowman CC, Clements JD. Differential biological and adjuvant activities of cholera toxin and Escherichia coli heat-labile enterotoxin hybrids. Infect Immun 2001;69(3):1528-35.
59. Dohi T, Rennert PD, Fujihashi K, Kiyono H, Shirai Y, Kawamura YI, Browning JL, McGhee JR. Elimination of colonic patches with lymphotoxin receptor-Ig prevents Th2 cell-type colitis. J Immunol 2001;167:2781-90.
60. Smith CA. Current concepts: are we vaccinating too much? Am Vet Med Assoc 1995;207: 421-5.
61. Holmes SJ. Review of recommendations of the advisory committee on immunization practices. Centers for disease control and prevention. Varicella vaccine. J Inf Dis 1996;174:S342-4.
62. Centers for Disease Contro, Update: Vaccine side effects, adverse reactions, contraindications, and precautions. MMWR 1996;45:RR-12.